- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03132792
AFPᶜ³³²T in Advanced HCC
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
This first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor. Those who did not tolerate or refused other therapies may also participate. The purpose of this study is to test the safety of genetically changed T cells that target alpha-fetoprotein (AFP) and find out what effects, if any, they have in subjects with liver cancer or other AFP expressing tumor types. This study is for subjects who have a blood test positive for appropriate HLA-A*02 P Group and have adequate AFP protein in blood or tumor, and whose noncancerous liver tissue has very little AFP protein (Liver only).
The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells.
The manufacturing of T cells takes about 1 month to complete. The T cells will be given back to the subject through an intravenous infusion after 3 days of chemotherapy. The study will evaluate three different cell dose levels in order to find out the target cell dose. Once the target cell dose is determined, additional subjects will be enrolled to further test the safety and effects at this cell dose.
Subjects will be hospitalized for at least 1 week after receiving their T cells back and then seen frequently by the Study Physician for the next 6 months. After that, subjects will be seen every three months. If subjects have disease progression or withdraw from the study, they will then be entered into a long-term follow up for safety monitoring. In long-term follow up, subjects will be seen every 6 months by their Study Physician for the first 5 years after the T cell infusion and annually for the next 10 years.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Marseille Cedex, France
- Paoli Calmettes Institute
-
Rennes, France
- Centre Eugene Marquis
-
Villejuif, France
- Institute Gustave Roussy
-
-
-
-
-
Barcelona, Spain, 08036
- University Hospital of Barcelona
-
Pamplona, Spain, 31008
- University Hospital of Navarra
-
-
-
-
-
Glasgow, United Kingdom
- Beatson West of Scotland Cancer Centre
-
London, United Kingdom, SE1 9RT
- Guy's Hospital
-
London, United Kingdom, W1T7HA
- NIHR UCLH Clinical Research
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic Arizona
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA
-
Los Angeles, California, United States, 90033
- USC/Norris Comprehensive Cancer Center
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute - Emory University
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Greenebaum Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Clinical Trial Referral Office
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University - School of Medicine
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Centre
-
Seattle, Washington, United States, 98109
- SCCA Immunotherapy Trials Intake
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Subject is ≥ 18 years and ≤ 75 years of age and has voluntarily agreed to participate by giving written informed consent in accordance with ICH GCP Guidelines and applicable local regulations.
- Histologically confirmed HCC, not amenable to transplant, resection. Subjects may undergo loco-regional therapy after enrollment but not at time of lymphodepletion. Or Histologically confirmed diagnosis of another AFP expressing tumor (e.g. cholangiocarcinoma).
- Measurable disease according to RECIST 1.1 criteria prior to lymphodepletion.
- Progressive disease following or intolerant of or refuses standard of care systemic therapy prior to lymphodepletion.
- Positive for any A*02:01 P group allele.
a) Group 1, 2, 3, (HCC) Subjects will be eligible for enrollment if they meet either one of these AFP expression criteria:
- AFP expression of ≥1+ in ≥20% of tumor cells by immunohistochemistry and their non-cancerous liver tissue has ≤5% cells stained for AFP at any intensity by immunohistochemistry.
- Serum AFP levels of ≥100ng/mL and their non-cancerous liver tissue has ≤5% cells stained for AFP at any intensity by immunohistochemistry.
6. b) Group 4 (other AFP expressing tumor types) Subjects will be eligible for enrollment if they meet either one of these AFP expression criteria:
o Serum AFP levels of ≥100ng/mL and their non-cancerous liver tissue (if applicable) has ≤5% cells stained for AFP at any intensity by immunohistochemistry.
7. Life expectancy of > 4 months 8. Child-Pugh score ≤ 6 9. Eastern Cooperative Oncology Group (ECOG) 0-1 10. Subject must have adequate organ function as defined in the protocol.
Key Exclusion Criteria:
- Positive for any of the HLA-A*02 allele other than HLA-A*02:01 P Group, HLA-A*02:03 P group or null alleles or positive for the following alleles: HLA-C*04:04 or HLA-B*51:03.
- Prior liver transplant
Received the following prior to leukapheresis:
- Cytotoxic chemotherapy, immune therapy and biological therapy within 3 weeks
- Corticosteroids or any other immunosuppressive therapy within 2 weeks. NOTE: Use of inhaled or topical steroids is not exclusionary
- Sorafenib/Regorafenib/Lenvatinib within 1 week
- Cabozantinib within 2 weeks
- Duration of treatment free intervals for any other anti-cancer therapies must be discussed with Adaptimmune Study Physician.
Received the following prior to lymphodepleting chemotherapy :
- Cytotoxic chemotherapy or loco-regional therapy within 3 weeks, liver directed radiation therapy within three months.
- Corticosteroids or any other immunosuppressive therapy within 2 weeks. NOTE: Use of inhaled or topical steroids is not exclusionary
- Bone/soft tissue directed palliative radiotherapy within 4 weeks.
- Investigational treatment or clinical trial within 4 weeks.
- Sorafenib/Regorafenib/Lenvatinib within 1 week.
- Cabozantinib within 2 weeks
- Prior cancer-directed immunotherapy within 4 weeks, including monoclonal antibodies against PD-1 receptor or ligand.
- Use of an experimental vaccine within 2 months in the absence of tumor response. The subject should be excluded if their disease is responding to an experimental vaccine given within 6 months
- Any previous gene therapy using an integrated vector
- Duration of treatment free intervals for any other anti-cancer therapies must be discussed with Adaptimmune Study Physician.
- Toxicity persisting from previous anti-cancer therapy of ≥ Grade 2 (except for non-clinically significant toxicities, e.g., alopecia, vitiligo). Subjects with Grade 2 toxicities that are deemed stable or irreversible (e.g. peripheral neuropathy) can be enrolled on a case-by-case basis with prior consultation and agreement with the Sponsor Study Physician.
- Major surgery within 4 weeks prior to lymphodepletion; subjects should have been fully recovered from any surgical related toxicities.
- Bleeding ≥ Grade 2 in the past 3 months prior to lymphodepletion
- Therapeutic anticoagulation from lymphodepletion until platelet count recovery (prophylactic heparin allowed)
- Clinically or radiographically detectable ascites (beyond trace/rim of ascites) or ascites requiring medication
- Clinically detectable hepatic encephalopathy or hepatic encephalopathy requiring medication
Active viral hepatitis Subjects positive for hepatitis B surface antigen not on antiviral treatment/prophylaxis or subjects with detectable hepatitis B DNA
- Subjects with resolved (surface antigen negative, core antibody positive) or chronic stable (surface antigen positive) hepatitis B on antiviral treatment/prophylaxis with DNA levels of ≤100 IU/mL are allowed with HBV DNA monitoring after treatment
- Subjects with hepatitis C allowed provided they meet all other eligibility criteria
- Positive serology for HIV
- Positive serology for HTLV 1 or 2
- History of chronic or recurrent (within the last year) severe autoimmune or immune mediated disease requiring steroids or other immunosuppressive treatments. Subjects with history of idiopathic autoimmune hepatitis are excluded. Subjects who experienced hepatitis during treatment with check point inhibiting antibodies are not excluded.
- Subject has brain metastases.
- Other active malignancy besides HCC or other eligible AFP expressing tumor types within 3 years.
- Electrocardiogram (ECG) showing clinically significant abnormality at Screening or showing a QTc interval ≥450 msec in males and ≥470 msec in females (≥480 msec for subjects with Bundle Branch Block (BBB) over consecutive ECGs).
- Bacterial or opportunistic infection within 3 months of treatment (upper respiratory infection and uncomplicated urinary tract infection allowed)
Uncontrolled intercurrent illness considered by the Investigator to add appreciable risk to study participation, including but not limited to:
- Clinically significant cardiac disease defined by CHF New York Heart Association (NYHA) > Class 1; uncontrolled clinically significant arrhythmia in last 6 months; Acute Coronary Syndrome (ACS) (angina or myocardial infarction) in last 6 months.
- Oxygen dependent lung disease.
- Clinically significant psychiatric illness/social situations that would limit compliance with study requirements.
- History of stroke or central nervous system bleeding; transient ischemic attack (TIA) or reversible ischemic neurologic deficit (RIND) in last 6 months.
- Pregnant or breastfeeding
- Alcohol or illicit drug dependency
- Known contraindication to cyclophosphamide, fludarabine, mesna, G-CSF or other agents associated with study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Autologous genetically modified AFPᶜ³³²T cells
|
Infusion of autologous genetically modified AFPᶜ³³²T cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with dose-limiting toxicity (DLT) and adverse events (AEs) and determination of optimally tolerated dose range, including serious adverse events (SAE).
Time Frame: 2 years
|
Determine if treatment with autologous genetically modified T cells, (AFPᶜ³³²T) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments including chemistry, hematology, coagulation, cardiac assessments including ECG, and cardiac Troponin
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with a confirmed Complete Response (CR) or Partial Response (PR)
Time Frame: 2 years
|
Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1
|
2 years
|
Interval between the date of first T cell infusion dose and first documented evidence of CR or PR
Time Frame: 2 years
|
Evaluation of the efficacy of the treatment by assessment of time to first response
|
2 years
|
Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause
Time Frame: 2 years
|
Evaluation of the efficacy of the treatment by assessment of duration of response
|
2 years
|
Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause
Time Frame: 2 years
|
Evaluation of the efficacy of the treatment by assessment of duration of stable disease
|
2 years
|
Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause
Time Frame: 2 years
|
Evaluation of the efficacy of the treatment by assessment of progression-free survival
|
2 years
|
Interval between the date of first T cell infusion and date of disease progression or death due to any cause
Time Frame: 2 years
|
Evaluation of the efficacy of the treatment by assessment of overall survival
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard S Finn, MD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADP-0033-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Cancer
-
Ethicon, Inc.CompletedCarcinoma, Hepatocellular | Hepatocellular Carcinoma | Hepatocellular Cancer | Cancer, HepatocellularKorea, Republic of
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Asan Medical CenterSeoul National University Hospital; Hanyang University; Soon Chun Hyang UniversityRecruitingHepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IVKorea, Republic of
-
Allison O'Neill, MDRecruitingLiver Cancer | Fibrolamellar Carcinoma | Hepatocellular Carcinoma, Childhood | Liver Cancer, PediatricUnited States
-
Medical College of WisconsinWithdrawnHepatocellular Carcinoma | Liver Cancer | Hepatoma | Hepatocellular CancerUnited States
-
Daiichi Sankyo, Inc.TerminatedAdvanced Solid Tumors | Hepatocellular Cancer (HCC)United Kingdom
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingStage III Hepatocellular Cancer (CNLC Staging)China
-
Henan Cancer HospitalNot yet recruiting
Clinical Trials on Autologous genetically modified AFPᶜ³³²T cells
-
AdaptimmuneCompletedCarcinoma | Non-Small Cell Lung CancerUnited States, Spain, United Kingdom, Canada
-
AdaptimmuneCompletedMelanoma | Head and Neck Cancer | Urothelial Carcinoma | Bladder Urothelial CarcinomaUnited States, Canada, Spain
-
AdaptimmuneTerminated
-
AdaptimmuneActive, not recruitingMelanoma | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Urinary Bladder Cancer | Synovial Sarcoma | Gastroesophageal Junction | Myxoid Round Cell LiposarcomaUnited States, Canada
-
GlaxoSmithKlineCompleted
-
Nanfang Hospital of Southern Medical UniversityGuangdong Yike Gene Science and Technology CO.,LtdUnknownBeta Thalassemia MajorChina
-
University of CologneUnknownCD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis FungoidesGermany
-
Tessa TherapeuticsActive, not recruitingAnaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)United States
-
University of PennsylvaniaCompleted